Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Hong-qing Zhuang, Zhi-yong Yuan, Jun Wang, Ping Wang, Lu-jun Zhao & Bai-lin Zhang. (2012) Research progress on criteria for discontinuation of EGFR inhibitor therapy. OncoTargets and Therapy 5, pages 263-270.
Read now
Read now
Parisa Yousefpour, Fatemeh Atyabi, Ebrahim Vasheghani-Farahani, Ali-Akbar Mousavi Movahedi & Rassoul Dinarvand. (2011) Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. International Journal of Nanomedicine 6, pages 1977-1990.
Read now
Read now
Filippo Montemurro, Stefania Redana, Giorgio Valabrega & Massimo Aglietta. (2007) Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. Expert Opinion on Pharmacotherapy 8:8, pages 1179-1188.
Read now
Read now
Filippo Montemurro, Giorgio Valabrega & Massimo Aglietta. (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy 7:2, pages 257-268.
Read now
Read now
Riccardo Ponzone & Piero Sismondi. (2005) Selected highlights from the 27th San Antonio Breast Cancer Symposium. Expert Opinion on Pharmacotherapy 6:7, pages 1257-1267.
Read now
Read now
Filippo Montemurro, Stefania Redana, Giorgio Valabrega & Massimo Aglietta. (2005) Controversies in breast cancer: adjuvant and neoadjuvant therapy. Expert Opinion on Pharmacotherapy 6:7, pages 1055-1072.
Read now
Read now
Filippo Montemurro & Massimo Aglietta. (2004) Selected Highlights from the 26th San Antonio Breast Cancer Symposium. Expert Opinion on Pharmacotherapy 5:4, pages 981-989.
Read now
Read now
Articles from other publishers (35)
Ernesto A.B.F. Lima, Reid A.F. Wyde, Anna G. Sorace & Thomas E. Yankeelov. (2022) Optimizing combination therapy in a murine model of HER2+ breast cancer. Computer Methods in Applied Mechanics and Engineering 402, pages 115484.
Crossref
Crossref
Na Re Ko, Se Young Van, Sung Hwa Hong, Seog-Young Kim, Miran Kim, Jae Seo Lee, Sang Ju Lee, Yong-kyu Lee, Il Keun Kwon & Seung Jun Oh. (2020) Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy. Nanomaterials 10:1, pages 91.
Crossref
Crossref
Abhishesh Kumar Mehata, Shreekant Bharti, Priya Singh, Matte Kasi Viswanadh, Lakshmi Kumari, Poornima Agrawal, Sanjay Singh, Biplob Koch & Madaswamy S. Muthu. (2019) Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Colloids and Surfaces B: Biointerfaces 173, pages 366-377.
Crossref
Crossref
Jamunarani Veeraraghavan, Jiacheng Ma, Yiheng Hu & Xiao-Song Wang. (2016) Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Research and Treatment 158:2, pages 219-232.
Crossref
Crossref
Shabnam Tarvirdipour, Ebrahim Vasheghani-Farahani, Masoud Soleimani & Hassan Bardania. (2016) Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells. International Journal of Pharmaceutics 501:1-2, pages 331-341.
Crossref
Crossref
Vahid Ramezani, Alireza Vatanara, Abdolhossein Rouholamini Najafabadi, Mohammad Ali Shokrgozar, Alireza Khabiri & Mohammad Seyedabadi. (2014) A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying process. DARU Journal of Pharmaceutical Sciences 22:1.
Crossref
Crossref
Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat & Dennis J. Slamon. (2014) Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research 20:13, pages 3507-3520.
Crossref
Crossref
Filippo Montemurro & Maurizio Scaltriti. (2014) Biomarkers of drugs targeting HER-family signalling in cancer. The Journal of Pathology 232:2, pages 219-229.
Crossref
Crossref
MARIKE GABRIELSON & ELISABET TINA. (2013) The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. Oncology Reports 29:4, pages 1268-1274.
Crossref
Crossref
Kendra Garrison, Tobias Hahn, Wen-Cherng Lee, Leona E. Ling, Andrew D. Weinberg & Emmanuel T. Akporiaye. (2011) The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunology, Immunotherapy 61:4, pages 511-521.
Crossref
Crossref
O. L. Polanovski, E. N. Lebedenko & S. M. Deyev. (2012) ERBB oncogene proteins as targets for monoclonal antibodies. Biochemistry (Moscow) 77:3, pages 227-245.
Crossref
Crossref
Tobias Hahn, Deborah J Bradley-Dunlop, Laurence H Hurley, Daniel Von-Hoff, Stephen Gately, Disis L Mary, Hailing Lu, Manuel L Penichet, David G Besselsen, Brook B Cole, Tanisha Meeuwsen, Edwin Walker & Emmanuel T Akporiaye. (2011) The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer 11:1.
Crossref
Crossref
Valentina Rossi, Stefania Redana, Andrea Milani, Elena Geuna, Giorgio Valabrega, Massimo Aglietta & Filippo Montemurro. (2011) Trastuzumab in the adjuvant setting: a practical review. Therapy 8:2, pages 161-177.
Crossref
Crossref
Stefania Redana, Michela Donadio, Franco Nolè, Maria Elena Jacomuzzi, Alessandra Beano, Rossella Martinello, Anna Sapino, Giuseppe Viale, Massimo Aglietta & Filippo Montemurro. (2010) Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer 10:1.
Crossref
Crossref
Filippo Montemurro, Valentina Rossi, Franco Nolè, Stefania Redana, Michela Donadio, Rossella Martinello, Elena Verri, Giorgio Valabrega, Maria Cossu Rocca, Maria Elena Jacomuzzi, Giuseppe Viale, Anna Sapino & Massimo Aglietta. (2010) Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. The Oncologist 15:7, pages 665-672.
Crossref
Crossref
Neil A. O'Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O'Donovan & Dennis J. Slamon. (2010) Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics 9:6, pages 1489-1502.
Crossref
Crossref
Melissa J. LaBonte, Philipp C. Manegold, Peter M. Wilson, Will Fazzone, Stan G. Louie, Heinz-Josef Lenz & Robert D. Ladner. (2009) The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. International Journal of Cancer 125:12, pages 2957-2969.
Crossref
Crossref
Filippo Montemurro, Stefania Redana, Franco Nolè, Michela Donadio, Maria Elena Jacomuzzzi, Giorgio Valabrega, Giuseppe Viale, Anna Sapino & Massimo Aglietta. (2008) Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer 8:1.
Crossref
Crossref
Bingfeng Sun, Balu Ranganathan & Si-Shen Feng. (2008) Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29:4, pages 475-486.
Crossref
Crossref
Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim Akhurst, Daniel T. Milton, Erin Moore, Leslie Tyson, William Pao, Naiyer A. Rizvi, Lawrence H. Schwartz & Vincent A. Miller. (2007) Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. Clinical Cancer Research 13:17, pages 5150-5155.
Crossref
Crossref
G. Valabrega, F. Montemurro & M. Aglietta. (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology 18:6, pages 977-984.
Crossref
Crossref
Patricia A. Fetsch & Andrea Abati. (2007) The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagnostic Cytopathology 35:6, pages 319-328.
Crossref
Crossref
Rupert Bartsch, Catharina Wenzel, Dagmar Hussian, Ursula Pluschnig, Ursula Sevelda, Wolfgang Koestler, Gabriela Altorjai, Gottfried J Locker, Robert Mader, Christoph C Zielinski & Guenther G Steger. (2006) Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 6:1.
Crossref
Crossref
Massimiliano Mazzone & Paolo M. Comoglio. (2006) The Met pathway: master switch and drug target in cancer progression. The FASEB Journal 20:10, pages 1611-1621.
Crossref
Crossref
R. Merola, M. Mottolese, G. Orlandi, E. Vico, F. Cognetti, I. Sperduti, A. Fabi, G. Vitelli & A.M. Cianciulli. (2006) Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. European Journal of Cancer 42:10, pages 1501-1506.
Crossref
Crossref
Rupert Bartsch, Catharina Wenzel, Ursula Pluschnig, Dagmar Hussian, Ursula Sevelda, Gottfried J. Locker, Robert Mader, Christoph C. Zielinski & Guenther G. Steger. (2005) Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemotherapy and Pharmacology 57:5, pages 554-558.
Crossref
Crossref
John R. Ohlfest, Zachary L. Demorest, Yasuhiko Motooka, Isabelita Vengco, Seunguk Oh, Eleanor Chen, Frank A. Scappaticci, Rachel J. Saplis, Stephen C. Ekker, Walter C. Low, Andrew B. Freese & David A. Largaespada. (2005) Combinatorial Antiangiogenic Gene Therapy by Nonviral Gene Transfer Using the Sleeping Beauty Transposon Causes Tumor Regression and Improves Survival in Mice Bearing Intracranial Human Glioblastoma. Molecular Therapy 12:5, pages 778-788.
Crossref
Crossref
Dawn N. Waterhouse, Tetyana Denyssevych, Norma Hudon, Stephen Chia, Karen A. Gelmon & Marcel B. Bally. (2005) Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels. Pharmaceutical Research 22:6, pages 915-922.
Crossref
Crossref
Xianming Huang, Mary Bennett & Philip E. Thorpe. (2005) A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice. Cancer Research 65:10, pages 4408-4416.
Crossref
Crossref
Filippo Montemurro & Massimo Aglietta. (2005) Incorporating Trastuzumab into the Neoadjuvant Treatment of HER2-Overexpressing Breast Cancer. Clinical Breast Cancer 6:1, pages 77-80.
Crossref
Crossref
G Bussolati, F Montemurro, L Righi, M Donadio, M Aglietta & A Sapino. (2005) A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. British Journal of Cancer 92:7, pages 1261-1267.
Crossref
Crossref
M. Stern & R. Herrmann. (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology 54:1, pages 11-29.
Crossref
Crossref
Yong Wei & Jessie L.-S. Au. 2005. Integration/Interaction of Oncologic Growth. Integration/Interaction of Oncologic Growth
285
321
.
Filippo Montemurro, Ivana Sarotto, Laura Casorzo, Alberto Pisacane, Massimo Aglietta & Giovanni De Rosa. (2004) HER2 and Central Nervous System Metastasis in Patients with Breast Cancer. Clinical Breast Cancer 5:3, pages 232-234.
Crossref
Crossref
Athanasios Alexopoulos, M.V Karamouzis & G Rigatos. (2004) In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: General concepts and future perspectives. Seminars in Oncology 31, pages 25-30.
Crossref
Crossref